Compare · BDX vs RVP
BDX vs RVP
Side-by-side comparison of Becton Dickinson and Company (BDX) and Retractable Technologies Inc. (RVP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and RVP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 2028.1x RVP ($20.5M).
- Over the past year, BDX is down 12.3% and RVP is up 1.8% - RVP leads by 14.2 points.
- BDX has hit the wire 10 times in the past 4 weeks while RVP has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for RVP).
- Company
- Becton Dickinson and Company
- Retractable Technologies Inc.
- Price
- $151.22+1.14%
- $0.67-8.57%
- Market cap
- $41.65B
- $20.5M
- 1M return
- +4.55%
- +1.63%
- 1Y return
- -12.33%
- +1.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- 2001
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Retractable Technologies Inc.
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holder; allergy tray; IV safety catheter; Patient Safe syringes and Luer Caps; VanishPoint blood collection set; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest RVP
- Retractable Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by Retractable Technologies Inc.
- Retractable Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Retractable Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Retractable Technologies, Inc. Announces Workforce Reduction
- Retractable Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Retractable Technologies, Inc. Reports Results for 2025
- Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
- SEC Form 10-K filed by Retractable Technologies Inc.
- SEC Form DEFA14A filed by Retractable Technologies Inc.